Astrazeneca UK Limited

In response to the growing need for sustainable practices in pharmaceutical manufacturing, our project aims to transform the industry by incorporating cutting-edge technology and data-driven approaches to create eco-friendly factories for the future. Our vision is to revolutionise pharmaceutical manufacturing by integrating robotics and automation, along ...

Ensuring reliable access to affordable, safe, effective, sustainable, and high-quality 21st-century medicines requires 21st-century technologies and, crucially, harmonised, effective and innovative regulatory approaches. This UK regulatory science network aims to deliver the 21st-century regulatory science and innovation needed to unlock the benefits of t...

Oligonucleotides (oligos) are sequences of nucleotides monomers which usually contain between 15-25 nucleotides/ nucleotide-analogues, they offer promising treatment for a wide range of medical conditions. There are now 15 oligo drugs which have been approved between the EMA and FDA. In recent years, an **increasing number of oligos in clinical trials** h...

no public description

Injection under the skin (termed 'subcutaneous' injection) is a well-established and well-tolerated route of administration of certain drugs that cannot be swallowed as tablets or capsules. These include highly effective drugs based on large and fragile molecules, such as peptides and proteins (termed 'biotherapeutics'), including insulin. These drugs are...

Small amounts of impurities on the surfaces of pharmaceutical crystals (used in tablets and inhalers) can significantly affect the performance of the crystals. During drug crystallisation, byproducts of synthesis steps are likely to be "pushed" to the surface. The levels of such surface impurities are far too low to be of concern regarding patient toxicit...

.

To apply Solid-State NMR crystallography to provide better quality products and improved manufacturing processes for disordered active pharmaceutical ingredients such as hydrates.

Awaiting Public Project Summary

Only 1 in 10 of all new drugs makes it through clinical trails to become an approved medicine, which is a signifciant problem for the pharmaceutical industry. However if these failures are due to a lack of efficacy, then it may be possible to repurpose drugs in a new disease areas. Non-alcoholic fatty liver disease (NAFLD) presents a significant unmet med...

All new active pharmaceutical ingredients must undergo an environmental risk assessment (ERA) before being authorised. Currently tens of thousands of fish are used worldwide as part of API ERAs. Development of predictive in silico models has the potential to significantly reduce animal use (3Rs) and reduce R&D costs around the ERA of pharmaceuticals. Thes...